Rural New Mexico hospital may close its doors after $100M malpractice judgment

One of the biggest malpractice judgments in New Mexico history could cause a rural hospital to close its doors. The Rehoboth McKinley Medical Center has been ordered to pay a bond of more than $100 million. While the hospital plans to appeal, it still needs to pay up for the case to move forward. 

The hospital, according to its law firm, has negative net work of over $25.7 million. Further, the hospital leases the land on its own and does not own the property, leaving it without much collateral for a loan. 

In January, jurors awarded a patient and his family more than $68 million in damages following a botched hernia surgery that left him with severe, life-altering complications. The lawsuit was first filed in 2019.

The $100 million judgment includes punitive damages and interest on the $68 million bond. When all is said and done, the hospital could owe more than $130 million, its lawyers said. Once a final judgment is issued, Rehoboth McKinley will have 60 days to come up with the money. 

The hospital was given $12 million this year by the state to cover its costs, but the struggling hospital will need a lot more money if it continues operating. If it closes its doors, residents in Gallup, NM could be left without an emergency room and lose access to medical care.

For more, check out the full story from Source NM at the link below.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.